Viet NamTuberculosis profile
Population  2018 96 million
Estimates of TB burdenº, 2018 Number (thousands) Rate
(per 100 000 population)
Total TB incidence 174 (111–251) 182 (116–263)
HIV-positive TB incidence 6 (3.8–8.6) 6.2 (4–9)
MDR/RR-TB incidenceºº 8.6 (5.4–13) 9.1 (5.7–13)
HIV-negative TB mortality 11 (6.7–15) 11 (7–16)
HIV-positive TB mortality 2.2 (1.4–3.2) 2.3 (1.5–3.4)
Estimated proportion of TB cases with MDR/RR-TB, 2018
New cases 3.6% (3.4–3.8)
Previously treated cases 17% (17–18)
TB case notifications, 2018  
Total new and relapse 99 658
          - % tested with rapid diagnostics at time of diagnosis 20%
          - % with known HIV status 85%
          - % pulmonary 80%
          - % bacteriologically confirmedººº 70%
          - % children aged 0-14 years 2%
          - % women 27%
          - % men 71%
Total cases notified 102 171
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2018 57% (40–90)
TB patients facing catastrophic total costs, 2016 63% (58–67)
TB case fatality ratio (estimated mortality/estimated incidence), 2018 8% (4–12)
TB/HIV care in new and relapse TB patients, 2018 Number (%)
Patients with known HIV status who are HIV-positive 2 902 3%
          - on antiretroviral therapy 2 705 93%
Drug-resistant TB care, 2018
% of bacteriologically confirmed TB cases tested for rifampicin resistance ººº
          - New cases 82%
          - Previously treated cases 100%
Laboratory-confirmed cases* MDR/RR-TB: 3 126, XDR-TB: 61
Patients started on treatment* ** MDR/RR-TB: 3 110, XDR-TB: 198
MDR/RR-TB cases tested for resistance to second-line drugs 1 922
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2017 92% 102 193
Previously treated cases, excluding relapse, registered in 2017 87% 2 983
HIV-positive TB cases registered in 2017 79% 3 002
MDR/RR-TB cases started on second-line treatment in 2016 68% 2 450
XDR-TB cases started on second-line treatment in 2016 68% 28
TB preventive treatment, 2018  
% of HIV-positive people (newly enrolled in care) on preventive treatment 39%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
22% (21–25)
TB financing, 2019  
National TB budget (US$ millions) 72
Funding source: 14% domestic, 24% international, 62% unfunded
º Ranges represent uncertainty intervals
ºº MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
ººº Calculated for pulmonary cases only
* Includes cases with unknown previous TB treatment history
** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Incidence graph
   Total TB incidence
   New and relapse TB cases notified
   HIV-positive TB incidence

(Rate per 100 000 population per year)
Mortality graph
   HIV-negative TB mortality

Notified cases by age group and sex, 2018
age_sex_graph
____
 
FemalesMalesIncidence

Treatment success rate (%)
tx success graph
   New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__
Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2019-12-15 Data: www.who.int/tb/data